AbZelectPRO™- The Fast-Tracked CLD Platform Of The Future

AbZelectPRO™, a novel cell line development platform, is poised to revolutionize the production of biologics, including monoclonal antibodies (MAbs), bispecifics, trispecifics, Fc fusions, and other challenging-to-express proteins. Developed through a strategic partnership between Abzena and ProteoNic Biosciences, AbZelectPRO™ leverages the cutting-edge 2G UNic® vector technology, which significantly enhances production titers by optimizing multiple aspects of the protein expression process.

Abzena’s high-performing host cell line further amplifies the platform’s capabilities, ensuring efficient and cost-effective manufacturing even for difficult-to-express proteins. By adopting AbZelectPRO™, companies can streamline their development and production processes, reduce timelines, and achieve higher production levels, ultimately gaining a competitive advantage in the rapidly evolving landscape of biologic manufacturing.